Antipsychotic medications reduce relapse risk about 60% compared to placebo, according to the results of a Cochrane meta-analysis (Leucht et al. Lancet 2012;379:2063-2071. The analysis included 65 trials (n=6,493).
Psychiatry
Preventing relapses in schizophrenia: meta-analysis
January 9, 2013Antipsychotic medications reduce relapse risk about 60% compared to placebo, according to the results of a Cochrane meta-analysis (Leucht et al. Lancet 2012;379:2063-2071. The analysis included 65 trials (n=6,493).
Targeting glutamate: the end of the monoamine hypothesis?
December 5, 2012A number of recent papers have focused attention on the remarkable responses seen with glutamatergic agents in major depressive disorder (MDD), raising questions about the monoamine hypothesis of psychiatric disorders that has dominated biological psychiatry for a half century (Schildkraut JJ. Am J Psychiatry 1965;122:509-522).
Combination therapy superior to monotherapy for psychotic depression
November 7, 2012A meta-analysis of 8 treatment trials (n=762) has concluded that a combination of an antidepressant with an antipsychotic agent is better than either alone in the treatment of psychotic depression (Farahani & Correll. J Clin Psychiatry 2012;73:486-496).
Internet-based CBT an option for social anxiety disorder
June 6, 2012A Swedish study recently reported that cognitive-behavioural therapy (CBT) administered via the Internet was as effective as conventional cognitive-behavioural group therapy (CBGT) in the treatment of social anxiety disorder (Hedman et al. PLoS One 2011;6:e18001; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC3070741/pdf/pone.0018001.pdf).
In that study, 126 subjects with social anxiety disorder received either iCBT or CBGT for 15 weeks, then assessed with the Liebowitz Social Anxiety Scale. A total of 64% of subjects in the iCBT group and 45% in the CBGT group were classified as responders (non-inferior).